ProMIS Neurosciences Inc PMN

New Press Release - ProMIS Neurosciences Issues Letter to Shareholders

TORONTO, Ontario and CAMBRIDGE, Massachusetts, Jan. 08, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Issues Letter to ShareholderProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins...read article.

[M101]

At least he acknowledged two repeat concerns.  "... our tight control on cash management." "Our priorities are clear: to advance PMN310 through clinical development; to increase the Company’s visibility..."

[BottomBroker]

"We remain committed to advancing PMN310 through the rigorous clinical development process. Over the coming months, we will be laser-focused on completing the SAD clinical study with PMN310 and, subsequently, rolling into the Phase 1b Multiple Ascending Dose (MAD) study, subject to the availability of sufficient capital." Oh boy.....

[M101]

Yeah well that's the intentional ceiling and a forward looking statement, but why back out now?  Glass half full: there is no limit this election year to the money printing for maintaining the appearance of a functioning economy.